This Tech Stock Is 'Too Expensive,' Cramer Says: 'Wait For A Pullback'

Zinger Key Points
  • At EyePoint Pharmaceuticals, "the easy money has been made," Cramer says. "You got to find something else."
  • American Eagle "did screw up in the past," Cramer says. Instead, he recommends another clothing retailer.

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Camtek Ltd. CAMT is a "fabulous" company, but the stock is "too expensive." He recommended waiting for a pullback.

Cramer said he dislikes Novavax, Inc. NVAX entirely. "I’ve done so for a very, very long time, even when it was much, much higher," he added.

When asked about Atkore Inc. ATKR, he said, "When I do anything involving steel, I immediately default to Nucor Corporation NUE. You have to do that, it’s the best in show."

Don’t forget to check out our premarket coverage here

The "Mad Money" host said he is worried about the fact that Coinbase Global, Inc. COIN is "too expensive. Let it come in."

When asked about EyePoint Pharmaceuticals, Inc. EYPT, he said, "The easy money has been made here. You got to find something else."

Cramer said American Eagle Outfitters, Inc. AEO is good. "It did screw up in the past, though, I say Abercrombie & Fitch Co. ANF is much better," he added.

Price Action:

  • Shares of Abercrombie & Fitch gained 1.1% to close at $77.94.
  • American Eagle rose 1.1% to $20.16 on Thursday.
  • EyePoint Pharmaceuticals gained 9.5% to $21.18.
  • Coinbase rose 1.2% to $136.19 during Thursday’s session.
  • Atkore shares gained 1.8%, while Nucor added 0.6%.
  • Novavax shares fell 0.9% to $5.53, while Camtek fell 0.7% to close at $62.15 on Thursday.

Now Read This: $1.7M Bet On Erasca? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasNewsSmall CapTop StoriesMarketsMediaTrading IdeasCNBCJim Cramermad money Lightning Round
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!